[
  {
    "ts": null,
    "headline": "Analysts Split on AbbVie Inc. (ABBV) as BofA Cuts Target and HSBC Turns Bullish",
    "summary": "We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. TheFly reported on December 15 that Bank of America (BofA) lowered its price target for ABBV to $233 from $248 while maintaining a Neutral rating, reflecting a modestly reduced valuation outlook even as the company’s core business fundamentals remain solid. […]",
    "url": "https://finnhub.io/api/news?id=f57d45b494cbf9e5059c8502d990811f6801f13320eb4fea2c1af2a76b89fe95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766009604,
      "headline": "Analysts Split on AbbVie Inc. (ABBV) as BofA Cuts Target and HSBC Turns Bullish",
      "id": 137816865,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. TheFly reported on December 15 that Bank of America (BofA) lowered its price target for ABBV to $233 from $248 while maintaining a Neutral rating, reflecting a modestly reduced valuation outlook even as the company’s core business fundamentals remain solid. […]",
      "url": "https://finnhub.io/api/news?id=f57d45b494cbf9e5059c8502d990811f6801f13320eb4fea2c1af2a76b89fe95"
    }
  },
  {
    "ts": null,
    "headline": "Want Decades of Passive Income? Buy This ETF and Hold It Forever.",
    "summary": "Can one ETF deliver decades of dividend income? This unique high-quality yield generator deserves a spot on your watchlist.",
    "url": "https://finnhub.io/api/news?id=63416993780759904f5f8983cc4e0080f53464bc447d86f5cd4e8de72d3ac76b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765999860,
      "headline": "Want Decades of Passive Income? Buy This ETF and Hold It Forever.",
      "id": 137816633,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Can one ETF deliver decades of dividend income? This unique high-quality yield generator deserves a spot on your watchlist.",
      "url": "https://finnhub.io/api/news?id=63416993780759904f5f8983cc4e0080f53464bc447d86f5cd4e8de72d3ac76b"
    }
  },
  {
    "ts": null,
    "headline": "SCHD: This ETF Stinks",
    "summary": "Read why the SCHD ETF remains a stable choice for dividend growth, despite recent AI-driven underperformance.",
    "url": "https://finnhub.io/api/news?id=3b6d2a33cb106d0d459e3c8cce8bbdbf79f04cd264a88033ffe937ea315f9e5d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765997441,
      "headline": "SCHD: This ETF Stinks",
      "id": 137814928,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1364623580/image_1364623580.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Read why the SCHD ETF remains a stable choice for dividend growth, despite recent AI-driven underperformance.",
      "url": "https://finnhub.io/api/news?id=3b6d2a33cb106d0d459e3c8cce8bbdbf79f04cd264a88033ffe937ea315f9e5d"
    }
  },
  {
    "ts": null,
    "headline": "December 2025's Top Stocks Estimated Below Intrinsic Value",
    "summary": "As December 2025 unfolds, the U.S. stock market faces a challenging period with major indices like the S&P 500 and Dow Jones Industrial Average experiencing consecutive declines amid AI bubble concerns and rising unemployment rates. In such an environment, identifying undervalued stocks becomes crucial for investors seeking opportunities that may offer potential value relative to their intrinsic worth.",
    "url": "https://finnhub.io/api/news?id=9406492b9486a21a01376951a8578af9476adfc302ae81845aae4aa15073dcc5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765993084,
      "headline": "December 2025's Top Stocks Estimated Below Intrinsic Value",
      "id": 137816867,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "As December 2025 unfolds, the U.S. stock market faces a challenging period with major indices like the S&P 500 and Dow Jones Industrial Average experiencing consecutive declines amid AI bubble concerns and rising unemployment rates. In such an environment, identifying undervalued stocks becomes crucial for investors seeking opportunities that may offer potential value relative to their intrinsic worth.",
      "url": "https://finnhub.io/api/news?id=9406492b9486a21a01376951a8578af9476adfc302ae81845aae4aa15073dcc5"
    }
  },
  {
    "ts": null,
    "headline": "Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?",
    "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=42c7e88e8cfafefd15a2dd693983e7daf0e9f7a9839ce2877abdad6ee481310c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765980007,
      "headline": "Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?",
      "id": 137816868,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=42c7e88e8cfafefd15a2dd693983e7daf0e9f7a9839ce2877abdad6ee481310c"
    }
  },
  {
    "ts": null,
    "headline": "LENZ Therapeutics: Was That A Market Overreaction?",
    "summary": "LENZ Therapeutics, Inc.'s VIZZ shows promise despite a recent adverse event. Click for LENZ investment insights, risks, and growth potential in the eye care market.",
    "url": "https://finnhub.io/api/news?id=d801ea9f6b245786b2045a893cf1791357a6ed5d3ff95f4fdb8128fa45cd8c6a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765962139,
      "headline": "LENZ Therapeutics: Was That A Market Overreaction?",
      "id": 137811317,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2197063554/image_2197063554.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "LENZ Therapeutics, Inc.'s VIZZ shows promise despite a recent adverse event. Click for LENZ investment insights, risks, and growth potential in the eye care market.",
      "url": "https://finnhub.io/api/news?id=d801ea9f6b245786b2045a893cf1791357a6ed5d3ff95f4fdb8128fa45cd8c6a"
    }
  },
  {
    "ts": null,
    "headline": "Has AbbVie’s 24.6% 2025 Rally Left Further Upside After Strong DCF Signals?",
    "summary": "Wondering if AbbVie is still a smart buy after its huge run, or if the value has already been squeezed out of the stock? Let us unpack what the current price really implies about its long term prospects. AbbVie has climbed 24.6% year to date and 32.0% over the last year, even after a softer last month with a 3.7% pullback from recent highs to around $223.67. That mix of strong multi year gains and short term wobble is exactly when valuation matters most. Recently, investors have been...",
    "url": "https://finnhub.io/api/news?id=a00f2b3b2cb4d674d6e52f40a229350c64d2bb11c53bf681e77e987058b1a6b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765955362,
      "headline": "Has AbbVie’s 24.6% 2025 Rally Left Further Upside After Strong DCF Signals?",
      "id": 137816869,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Wondering if AbbVie is still a smart buy after its huge run, or if the value has already been squeezed out of the stock? Let us unpack what the current price really implies about its long term prospects. AbbVie has climbed 24.6% year to date and 32.0% over the last year, even after a softer last month with a 3.7% pullback from recent highs to around $223.67. That mix of strong multi year gains and short term wobble is exactly when valuation matters most. Recently, investors have been...",
      "url": "https://finnhub.io/api/news?id=a00f2b3b2cb4d674d6e52f40a229350c64d2bb11c53bf681e77e987058b1a6b0"
    }
  }
]